Alexion Soliris Label Mentions QOL Results Despite Reviewer Misgivings
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Labeling for Alexion's Soliris (eculizumab) includes a statement regarding improved health-related quality of life despite FDA reviewer concerns about adequacy of the QOL assessment